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Objective: The actual pathophysiology of interstitial cystitis (IC)/bladder pain syndrome (BPS) is still
uncertain. Immune or hypersensitivity mechanisms may play an important role in the pathogenesis of IC/
BPS. This study was designed to investigate and analyze serum immunoglobulin E (IgE) levels in patients
with IC/BPS.
Materials and methods: Patients with IC/BPS who were admitted for cystoscopic hydrodistention were
enrolled in this study. Blood samples were obtained to investigate their serum IgE levels. A serum IgE
level more than 200 IU/mL was considered abnormal. The patients' symptoms, visual analog scale (VAS)
scores, O'LearyeSant symptom (OSS) scores, cystometric bladder capacity (CBC), maximal bladder ca-
pacity (MBC), and grading of bladder glomerulation hemorrhage during cystoscopic hydrodistention
were recorded. Serum IgE levels were also investigated in women with stress urinary incontinence, who
served as the control group.
Results: Two hundred patients with IC/BPS and 35 controls were investigated. In total, 22 IC/BPS patients
(11%) had abnormal serum IgE levels. No abnormal serum IgE levels were detected in the controls. The
mean serum IgE level in IC/BPS patients and controls were 102.37 IU/mL± 250.68 IU/mL and 74.21 IU/
mL± 88.62 IU/mL, respectively (p ¼ 0.204). The VAS, OSS, CBC, MBC, and grading of glomerulations were
not signiﬁcantly correlated with serum IgE levels (p ¼ 0.317, 0.587, 0.774, 0.559, and 0.309, respectively).
The serum IgE levels were slightly higher in men than in women, although the difference was not sig-
niﬁcant (152.98 IU/mL ± 201.73 IU/mL vs. 94.87 IU/mL± 262.54 IU/mL, p ¼ 0.183).
Conclusion: In this study, 11% of patients with IC/BPS had IgE level more than 200 IU/mL, but the mean
serum IgE level was not higher than the controls. Aggravating factors such as food or environmental
substance should be carefully investigated in IC/BPS patients with elevated serum IgE levels.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a clinical
syndrome characterized by bladder pain and urinary frequency.1
The prevalence of IC/BPS ranges from 52 to 500/100,000 in
women comparedwith 8e41/100,000 inmen, and its incidence has
increased globally in recent years.2 Although many studies have
investigated the pathophysiology of IC/BPS in the past 20 years, it
remains a mystery. Many different hypotheses had been proposed,
including infection, inﬂammation, autoimmune mechanisms, de-
fects in the urothelial glycosaminoglycan layer, and centralBuddhist Tzu Chi General
0, Taiwan.
ociation. Published by Elsevier Taneurologic mechanisms.3 The etiology or pathogenesis of IC/BPS
might not be the same in every patient.
The histopathology of IC/BPS is not universal or speciﬁc. In a
previous study, 55% patients with IC/BPS had a normal bladder
histology, which was indistinguishable from that in controls.4
However, some bladder specimens of patients with IC/BPS were
characterized by mononuclear inﬂammation and mast cell acti-
vation.4 Eosinophil inﬁltration has also been found in some pa-
tients with IC/BPS.4 Liu et al5 quantitatively evaluated the
expression of junction protein E-cadherin, tight junction protein
zonula occludens, and activated mast cells in the bladder wall
using immunoﬂuorescence staining and found signiﬁcantly
increased numbers of mast cells in biopsy specimens from pa-
tients with IC/BPS compared with those from normal controls.5
The vasoactive amines, cytokines, and chemokines released by
mast cells might play an important role in the pathogenesis of IC/iwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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anaphylatoxins, neuropeptides, cytokines, and immunoglobulin E
(IgE).7
Mast cells and IgE are essential components of allergic inﬂam-
mation, and a previous study suggested that elevated serum IgE
levels could be detected in some hypersensitivity diseases such as
asthma and allergic rhinitis.8 Yamada9 performed cutaneous IgE
radioallergosorbent tests (RASTs) to identify possible allergens in
patients with IC/BPS, and carried out intravesical provocation tests
with the IgE-RAST-positive antigens. The IgE-RAST-positive antigen
was identiﬁed in four of ﬁve patients. In another study, approxi-
mately 80% of IC/BPS patients (children and adolescents) had
complications of allergic diseases.10 Jhang et al11 also found
increased serum IgE levels in patients with ketamine-related
cystitis and in that study, the maximal bladder capacity (MBC)
was correlated with the serum IgE level. IgEemast cell-mediated
inﬂammation in the bladder might participate in the pathogen-
esis of IC/BPS, and abnormal elevation of the serum IgE level might
be detected. This study was designed to investigate the serum IgE
level in patients with IC/BPS and its correlation with clinical
symptoms.
2. Materials and methods
Patients with IC/BPS who were admitted to Hualien Tzu Chi
General Hospital for treatment from 2008 to 2014 were enrolled in
this study. Their comprehensive clinical symptoms, disease history,
blood tests including a complete blood count and biochemistry
study, urinalysis, and urodynamic study were investigated in our
clinic. Patients who did not meet the National Institute of Diabetes
and Digestive and Kidney Diseases criteria for IC/PBS were excluded
before enrollment.12 All patients underwent cystoscopic hydro-
distention during hospitalization. The hydrodistention was per-
formed under general or spinal anesthesia with direct vision by
cystoscopy and irrigation ﬂuid was instilled into the bladder at a
pressure of 80 cmH2O. The diagnosis of IC/PBS was conﬁrmed by
ﬁndings of glomerulation hemorrhage during cystoscopic hydro-
distention. All of these patients had failed treatment with oral
pentosan polysulfate, pain control drugs, and lifestyle modiﬁcation.
Patients who had allergic rhinitis, allergic dermatitis, allergic
enterocolitis, drug allergies, or evidence of infection in any organ in
the previous month were excluded. Patients with pyuria on urinal-
ysis, a history of urinary tract surgery, malignant neoplasm, and se-
vere systemic disease requiring hospitalization in the previous
monthwere alsoexcluded fromthis study. SerumIgE levelswere also
investigated in the control group, which consisted of patients with
stress urinary incontinence without any allergic disease history.
Symptom severity was evaluated in patients using the O'Lear-
yeSant symptom (OSS) score and pain was evaluated using the vi-
sual analog scale (VAS) score. The cystometric bladder capacity
(CBC) results in the urodynamic study were recorded. The study
patients were classiﬁed into ulcer or nonulcer groups according to
cystoscopic ﬁndings. The MBC and grading of glomerulation hem-
orrhage (graded from0 to4, indicatingnone,mild,moderate, severe,
and ulcerated, respectively) during cystoscopic hydrodistention
were also recorded.13 Blood samples were collected during cysto-
scopic hydrodistention and serum IgE levels were determined. The
serum IgE level was measured using a solid-phase immunoassay
(Phadia speciﬁc immunoglobulin FEIA, Uppsala, Sweden), and a
serum IgE level more than 200 IU/mL was considered abnormal.14 If
the patients agreed, bladder mucosal tissues measuring about
2  2 mm2 were obtained during cystoscopic hydrodistention.
The bladder tissues were investigated for mast cell activation by
measuring the tryptase level. Biopsy specimens were embedded in
optimal cutting temperature media and stored at 80C. Thesections were incubated overnight at 4C with primary antibodies
to antihuman tryptase (Chemicon, Temecula, CA, USA). Immuno-
ﬂuorescence tryptase assays were quantiﬁed by counting the
number of positively stained cells/total cells/unit area (4 mm2), and
shown as the percentage of positive cells/100 total cells. Patients
were subsequently treated with intravesical onabotulinum toxin
(Botox) injections or intravesical hyaluronic acid (Cystistat) instal-
lation. The treatment outcomes were assessed using the Global
Response Assessment (GRA) tool 3 months after initial treatment.
Patients were requested to rate their bladder symptoms compared
with baseline on a 7-point centered scale [markedly (3), moder-
ately (2), slightly worse (1), no change (0), slightly (þ1),
moderately (þ2), or markedly improved (þ3)].15
The baseline OSS, VAS, CBC, and MBC values were compared be-
tween IC/BPS patients with normal and abnormal serum IgE levels
using the independent t test. The correlations of these parameters
with serum IgE were investigated. The GRA scores were also
compared between patients with normal and abnormal serum IgE
levels. The correlation between expressions of tryptase and serum
IgE was also investigated. Statistical assessments were considered
signiﬁcant when p is less than 0.05. Statistical analysis was per-
formed using SPSS version 15 (SPSS Inc, Chicago, IL, USA). This study
was approved by the Institutional Review Board and Ethics Com-
mittee of Hualien Tzu Chi hospital. Each patient was informed about
the study rationale and procedures before enrollment in the study;
written, informed consent was obtained before treatment.
3. Results
A total of 200 patients including 38 men and 162 women were
recruited to this study and completed initial investigations. The
mean age of these patients was 49.36 years ± 13.54 years (mean age
of male patients, 48.52 years ± 12.77 years; mean age of female
patients, 49.55 years). The serum IgE level was investigated in 35
female controls (mean age 53.4 years ± 12.12 years). There was no
signiﬁcant difference in age between IC/BPS patients and controls.
The mean serum IgE level of the IC/BPS patients was 102.37 IU/
mL± 250.68 IU/mL, and the median serum IgE level was 39.5 IU/
mL. The mean serum IgE level in the control group was 74.21 IU/
mL± 88.62 IU/mL. There was no statistically signiﬁcant difference
in the serum IgE level between IC/BPS patients and the controls
(p ¼ 0.204). After excluding male patients in the IC/BPS group, the
difference between IC/BPS patients and controls was still not sig-
niﬁcant (p ¼ 0.215). Twenty-two (11%) of the 200 IC/BPS patients
had abnormal serum IgE levels. Three patients with abnormal IgE
levels, and 19 patients with normal serum IgE levels had a history of
allergy to drugs or food (p ¼ 0.732). None of the individuals in the
control group had an abnormal serum IgE level.
The mean serum IgE levels in male and female IC/BPS patients
were not signiﬁcantly different statistically (124.16 IU/
mL ± 160.66 IU/mL vs. 97.17 IU/mL± 267.90 IU/mL, respectively,
p ¼ 0.552). Twelve patients had ulcer-type IC/BPS. There was no
signiﬁcant difference in the mean serum IgE level between patients
with the ulcer and nonulcer types of IC/BPS (225.69 IU/
mL ± 590.36 IU/mL vs. 94.38 IU/mL± 212.28 IU/mL, respectively,
p ¼ 0.459). The age, VAS, OSS, CBC, MBC, and grading of glomer-
ulation hemorrhage after cystoscopic hydrodistention between
patients with normal and abnormal serum IgE levels were not
signiﬁcantly different (all p > 0.05; Table 1). The age, VAS, OSS, CBC,
MBC, and grading of glomerulation also did not signiﬁcantly
correlate with serum IgE levels (p¼ 0.157, 0.317, 0.587, 0.774, 0.559,
and 0.309, respectively). A total of 19 patients agreed to bladder
biopsies, and investigation of their tryptase level. The correlation
between the IgE level and expression of tryptase was not signiﬁcant
(p ¼ 0.958, r2 ¼ 0.001).
Table 1






Age (y) 54.59 ± 17.88 48.67 ± 12.78 0.146
CBC (mL) 271.73 ± 96.10 300.55 ± 118.49 0.369
OSS score 24.47 ± 5.78 24.74 ± 6.87 0.897
VAS score 5.73 ± 2.67 4.59 ± 2.57 0.108
MBC (mL) 635.29 ± 181.80 674.68 ± 180.36 0.402
Glomerulation hemorrhage grading 1.76 ± 1.09 1.75 ± 1.02 0.946
CBC ¼ cystometric bladder capacity; IgE ¼ immunoglobulin E; MBC ¼ maximal bladder capacity; OSS score ¼ O'LearyeSant symptom score; VAS ¼ visual analog
scale.
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injections and 31 patients received intravesical hyaluronic acid
installation. Among the patients who received onabotulinum toxin
injections, the mean GRA score was 1.70 ± 0.67 in those with
abnormal IgE (n ¼ 10) levels and 1.44 ± 0.86 in those with normal
IgE (n ¼ 90) levels, with no signiﬁcant difference (p ¼ 0.291).
Among the patients who received intravesical hyaluronic acid
installation, the mean GRA score was 1.33 ± 0.58 in those with
abnormal IgE levels (n ¼ 3) and 1.36 ± 0.83 in those with normal
serum IgE (n ¼ 28) levels; however, there was no signiﬁcant dif-
ference (p ¼ 0.962).4. Discussion
Previous studies have suggested that IC/PBS has a multifactorial
etiology that may act predominantly through one or more path-
ways resulting in the typical symptom complex.16 It is possible that
no single treatment is effective for all IC/BPS patients. One case
report revealed causative participation of inhalant allergens and
food components in urinary complaints.17 Elimination of food
products that resulted in the production of speciﬁc IgE antibodies
and positive skin reactions resulted in a favorable clinical response
in some IC/BPS patients.18 Hypersensitivity and bladder IgE have
also been reported to be associated with IC/BPS.8,11 In this study,
approximately 11% of IC/BPS patients had abnormal elevated serum
IgE level, whereas none of the individuals in the control group had
any abnormal serum IgE level. However, the mean serum IgE level
was not different between the two groups.
A report 20 years ago noted that acidic food, alcohol, coffee, and
tea increased IC pain in some IC/BPS patients.19 Friedlander et al20
also reported that up to 90% of patients with IC/BPS had sensitiv-
ities to a wide variety of comestibles. One commonly held theory
proposes that the dysregulated bladder urothelial barrier leads to
the migration of urinary solutes or cations across the urothelium
with subsequent provocation of IC/BPS symptoms.21,22 However,
these studies were small and underpowered investigations carried
out on few patients.20 In theory, cations passing through the uro-
thelium should not induce an inﬂammatory reaction in healthy
tissue. Hypersensitivity, which is characterized by a reaction
immediately following contact with innocuous antigens, is
compatible with the clinical history of IC/BPS, and is another
possible mechanism. According to histopathologic ﬁndings of
increasing mast cell inﬁltration in the suburothelium and elevated
serum IgE levels in some patients, we suggest that the IC/BPS in
some patients who are sensitive to foods might result from an
IgEemast cell-mediated inﬂammation response.
European Urology Association guidelines suggest that IC/BPS
patients should be classiﬁed by the ﬁndings of cystoscopic hydro-
distention and bladder biopsy.1 Leiby et al23 also reported that the
histopathological features in biopsy specimens from IC/BPS pa-
tients were signiﬁcantly correlated with the severity of symptoms.Mast cell inﬁltration in the suburothelium in IC/BPS cases has been
well reported in many studies, and the increasing expression of
mast cells could also be correlated with symptoms.4,5 Mast cell-
mediated inﬂammation plays an important role in inﬂammation
in IC/BPS patients. Mast cells are stimulated by cross-linking of IgE
bound to surface receptors (FcεRI) and by speciﬁc antigens.24 Mast
cell activation, development, and migration are mediated by IgE.24
Mast cells and IgE have been so convincingly linked to the patho-
physiology of allergic reactions that it can be difﬁcult to think of
them in other contexts.25 However, serum IgE is not a good
biomarker for a hypersensitivity disease. In one study, the mean
serum IgE was not elevated and had poor correlation with clinical
symptoms, even in allergic rhinitis.26 In this study, the mean serum
IgE level in IC/BPS was not signiﬁcantly higher than that in the
normal controls (102.37 IU/mL ± 250.68 IU/mL vs. 74.21 IU/
mL± 88.62 IU/mL, p ¼ 0.204), and serum IgE levels were also not
correlated with symptoms. The mast cell activity in immuno-
chemical staining and serum IgE also did not have a signiﬁcant
correlation. The half-life of IgE could be weeks to months if it is
bound to cells in tissue, but would be only about 6 hours when IgE
is free in the plasma.27 IgEemast cell-mediated inﬂammation
might participate in the pathogenesis in some IC/BPS cases, but the
short half-life of serum IgE might lead to a poor correlation with
clinical symptoms.
Our study is a preliminary investigation about the possible
relation of IgE and IC/BPS. It implies the pathogenic association
between IC/BPS and hypersensitivity, at least in some of these pa-
tients. Because some patients had abnormal elevation of serum IgE
levels, we suggest that physicians should investigate for any
aggravating factors of IC/BPS symptoms in these patients (such as
food or environmental substance). Themain limitation of this study
was the lack of a well-accepted deﬁnition of normal serum IgE in
middle-aged adults, and therefore, the deﬁnition of abnormal
serum IgE might be inappropriate. The control group only included
women, but the study group included 19% male patients. We could
not eliminate the sex difference and prostate inﬂuence between the
two groups. The mean serum IgE might decrease with age and fe-
male sex.28 In the control group, some patients with stress urinary
incontinence may also have urgency/frequency or other urologic
conditions, and this might affect the serum IgE level. These data
might be heavily weighted by some extreme values. Further
immunohistochemical studies investigating local deposition of IgE
in bladder specimens, in vitro stimulation tests, and patch tests of a
large IC/BPS cohort might be helpful in this regard. The correlation
between serum IgE and mast cell inﬁltration in the suburothelium
should also be investigated.5. Conclusion
Elevated serum IgE level (>200 IU/mL) was found in 11% pa-
tients with IC/BPS. However, the mean serum IgE levels in these
J.-F. Jhang, H.-C. Kuo / Urological Science 26 (2015) 202e205 205patients were not higher than those in the controls. While exam-
ining IC/BPS patients with elevated serum IgE levels, physicians
should be careful if their patients are allergic to any substance that
could induce or aggravate the symptoms.
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